| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
MEI Pharma Inc (NASDAQ: MEIP)
MEIP Technical Analysis
5
| As on 18th Jun 2025 MEIP SHARE Price closed @ 2.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.50 & Strong Sell for SHORT-TERM with Stoploss of 4.77 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MEIPSHARE Price
| Open | 2.20 | Change | Price | % |
| High | 2.29 | 1 Day | 0.00 | 0.00 |
| Low | 2.20 | 1 Week | 0.04 | 1.81 |
| Close | 2.25 | 1 Month | 0.13 | 6.13 |
| Volume | 4557 | 1 Year | -3.76 | -62.56 |
| 52 Week High 6.15 | 52 Week Low 1.86 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| HCTI | 0.03 | 50.00% |
| GNLN | 0.01 | 0.00% |
| NVDA | 145.48 | 0.94% |
| APVO | 5.13 | 81.91% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| TSLA | 322.05 | 1.80% |
| INTC | 21.49 | 3.32% |
| OPEN | 0.58 | 1.75% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MEIP Daily Charts |
MEIP Intraday Charts |
Whats New @ Bazaartrend |
MEIP Free Analysis |
|
|
MEIP Important Levels Intraday
| RESISTANCE | 2.42 |
| RESISTANCE | 2.37 |
| RESISTANCE | 2.33 |
| RESISTANCE | 2.30 |
| SUPPORT | 2.20 |
| SUPPORT | 2.17 |
| SUPPORT | 2.13 |
| SUPPORT | 2.08 |
MEIP Forecast June 2025
| 4th UP Forecast | 5.06 |
| 3rd UP Forecast | 4.16 |
| 2nd UP Forecast | 3.6 |
| 1st UP Forecast | 3.05 |
| 1st DOWN Forecast | 1.45 |
| 2nd DOWN Forecast | 0.9 |
| 3rd DOWN Forecast | 0.34 |
| 4th DOWN Forecast | -0.56 |
MEIP Weekly Forecast
| 4th UP Forecast | 3.33 |
| 3rd UP Forecast | 2.98 |
| 2nd UP Forecast | 2.77 |
| 1st UP Forecast | 2.56 |
| 1st DOWN Forecast | 1.94 |
| 2nd DOWN Forecast | 1.73 |
| 3rd DOWN Forecast | 1.52 |
| 4th DOWN Forecast | 1.17 |
MEIP Forecast2025
| 4th UP Forecast | 11.5 |
| 3rd UP Forecast | 8.53 |
| 2nd UP Forecast | 6.7 |
| 1st UP Forecast | 4.87 |
| 1st DOWN Forecast | -0.37 |
| 2nd DOWN Forecast | -2.2 |
| 3rd DOWN Forecast | -4.03 |
| 4th DOWN Forecast | -7 |
MEI Pharma Inc ( NASDAQ USA Symbol : MEIP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MEIP Business Profile
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Address: 11455 El Camino Real, San Diego, CA, United States, 92130
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service